Soluble Concentrations of the Interleukin Receptor Family Member ST2 and &bgr;-Blocker Therapy in Chronic Heart Failure

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation: Heart Failure

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCHEARTFAILURE.113.000457PMID 24114865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).

  2013cited by this paper
• Hybrid CCTA/IVUS: breaking the traditional boundaries of coronary imaging.

  2012cited by this paper
• High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure

  2011cited by this paper
• Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.

  2011cited by this paper
• Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.

  2010cited by this paper
• Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.

  2010cited by this paper
• Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling

  2009cited by this paper
• Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea

  2009cited by this paper
• Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.

  2008cited by this paper
• IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.

  2007cited by this paper
• Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction

  2002cited by this paper
• Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

  2002cited by this paper
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study

  2002cited by this paper
• Endogenous Cyclic AMP-Adenosine Pathway Regulates Cardiac Fibroblast Growth

  2001cited by this paper
• Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

  2001cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

  1997cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease

  1997cited by this paper
• Molecular and cellular mechanisms of myocardial failure.

  1997cited by this paper
• Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.

  1995cited by this paper
• Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.

  1995cited by this paper
• Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte

  1992cited by this paper
• Myocyte Hypertrophy in Neonatal Rat Heart Cultures and Its Regulation by Serum and by Catecholamines

  1982cited by this paper

• Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study

  2024cites this paper
• Clinical markers in heart failure: a narrative review

  2024cites this paper
• Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure

  2024cites this paper
• High Soluble Suppression of Tumorigenicity-2 (sST2) is A Risk Factor for Rehospitalization and Mortality in Chronic Heart Failure Patients with Reduced Ejection Fraction

  2024influential citation
• Inflammation in heart failure: pathophysiology and therapeutic strategies

  2024cites this paper
• Prognostic Value of sST2 in Heart Failure

  2023cites this paper
• Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?

  2023cites this paper
• Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review

  2023cites this paper
• Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction

  2022cites this paper
• Biomarkers in heart failure: Relevance in the clinical practice.

  2022cites this paper
• Multidimensional Approach of Heart Failure Diagnosis and Prognostication Utilizing Cardiac Imaging with Biomarkers

  2022cites this paper
• Biomarker Development in Cardiology: Reviewing the Past to Inform the Future

  2022cites this paper
• Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers.

  2022cites this paper
• Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases

  2022cites this paper
• Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy

  2022cites this paper
• Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure

  2022cites this paper
• Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure

  2022cites this paper
• Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance

  2022cites this paper
• Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective

  2022cites this paper
• Soluble ST2: a valuable prognostic marker in heart failure

  2022cites this paper
• Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n’ Jill

  2021cites this paper
• Biomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failure

  2021cites this paper
• Clinical Translation of Discoveries in Cardiomyocyte Biology

  2021cites this paper
• Biomarkers Utility: At the Borderline between Cardiology and Neurology

  2021cites this paper
• A Novel Paradigm Based on ST2 and Its Contribution towards a Multimarker Approach in the Diagnosis and Prognosis of Heart Failure: A Prospective Study during the Pandemic Storm

  2021cites this paper
• Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

  2021cites this paper
• Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology

  2021cites this paper
• Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

  2021cites this paper
• Advancements in biomarkers for cardiovascular disease: diagnosis, prognosis, and therapy

  2021cites this paper
• Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week.

  2021cites this paper
• Soluble ST2 biomarker analysis for fibrosis development in atrial fibrillation. A case control study

  2021cites this paper
• The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19

  2021cites this paper
• Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty

  2021cites this paper
• Time‐sensitive approach in the management of acute heart failure

  2020cites this paper
• Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure.

  2020cites this paper
• Soluble ST2: a complex and diverse role in several diseases.

  2020cites this paper
• The partnership between renalase and ejection fraction as a risk factor for increased cardiac remodeling biomarkers in chronic heart failure patients

  2020cites this paper
• A review of biosensor technologies for blood biomarkers toward monitoring cardiovascular diseases at the point-of-care.

  2020cites this paper
• STADE‐HF (sST2 As a help for management of HF): a pilot study

  2020cites this paper
• Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2

  2020cites this paper
• Clinical value of soluble ST2 in cardiology.

  2020cites this paper
• Correlation between Suppression of Tumorigenicity-2 with Left Ventricular Geometry, Left Ventricular Ejection Fraction and Quality of Life in Systolic Heart Failure Patients

  2020cites this paper
• sST2 as a value-added biomarker in heart failure.

  2020cites this paper
• IL-33/sST2 axis in The Cardiovascular System: A Brief Review

  2020cites this paper
• Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community

  2020cites this paper
• Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction.

  2020cites this paper
• Reappraisal of Inflammatory Biomarkers in Heart Failure

  2020cites this paper
• Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction

  2019cites this paper
• Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.

  2019cites this paper
• sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure

  2019cites this paper
• Biomarkers to Assess and Guide the Management of Heart Failure

  2019cites this paper
• Soluble ST2 – a new biomarker in heart failure

  2019cites this paper
• Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.

  2019cites this paper
• [Soluble ST2 - as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure].

  2019cites this paper
• Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction

  2019cites this paper
• The predictive role for ST2 in patients with acute coronary syndromes and heart failure.

  2019cites this paper
• Evolving Use of Biomarkers in the Management of Heart Failure

  2019cites this paper
• Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction.

  2018cites this paper
• Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial.

  2018cites this paper
• Soluble ST2 in Heart Failure.

  2018cites this paper
• Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction

  2018influential citation
• The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery

  2018cites this paper
• Novel biomarkers in heart failure. What they add in daily clinical practice?

  2018cites this paper
• Established and Emerging Roles of Biomarkers in Heart Failure

  2018cites this paper
• IL-33/ST2 Axis in Organ Fibrosis

  2018cites this paper
• sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction

  2018cites this paper
• Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies.

  2018cites this paper
• Novel biomarkers of cardiovascular disease: Applications in clinical practice

  2018cites this paper
• Biomarkers and Heart Failure

  2018cites this paper
• ST2 elevation in heart failure, predictive of a high early mortality

  2018cites this paper
• Future biomarkers in cardiology: my favourites

  2018cites this paper
• NEW BIOMARKERS OF HEART FAILURE : DIAGNOSTIC AND PROGNOSTIC VALUE OF NT-proBNP AND INTERLEUKIN RECEPTOR FAMILY MEMBER ST 2

  2018influential citation
• Is soluble ST 2 a new marker in heart failure ?

  2018cites this paper
• Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives

  2017cites this paper
• Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study

  2017cites this paper
• Using Biomarkers to Guide Heart Failure Therapy.

  2017cites this paper
• Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis.

  2017cites this paper
• Community detection of non-ischemic stage B heart failure

  2017cites this paper
• Predictors of Long-Term Mortality in Patients With Acute Heart Failure.

  2017cites this paper
• Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates

  2017cites this paper
• Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

  2017cites this paper
• Using biomarkers to guide heart failure management

  2017cites this paper
• Dosage du récepteur soluble sST2 : perspectives

  2017cites this paper
• Novel Biomarkers of Heart Failure.

  2017cites this paper
• Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring.

  2017cites this paper
• Redefining the role of biomarkers in heart failure trials: expert consensus document

  2017cites this paper
• Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure.

  2017cites this paper
• Novel biomarkers in heart failure: How they change clinical decision?

  2017cites this paper
• Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction.

  2017cites this paper
• Soluble ST 2 Testing : A Promising Biomarker in the Management of Heart Failure

  2016cites this paper
• The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.

  2016cites this paper
• The World is Changing – Are We Ready ? ST 2 and galectin-3 : ready for prime time ?

  2016cites this paper
• Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure

  2016cites this paper
• Galectin-3 After Heart Transplantation: Does it Get Better?

  2016cites this paper
• Rola krążącego receptora dla IL-33 (sST2) w monitorowaniu terapii niewydolności serca

  2016influential citation
• FEP Medical Policy Manual

  2016cites this paper
• The search for efficient diagnostic and prognostic biomarkers of heart failure.

  2016cites this paper
• Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF.

  2016cites this paper
• Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials

  2016cites this paper
• Clinical relevance of sST2 in cardiac diseases

  2016cites this paper